TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07291076: ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)

Sponsor: Bristol-Myers Squibb · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 198 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$471,240

Rescue Site Savings

+$314,160

Unlock Full NCT07291076 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07291076 Rescue Dossier →